Abstract
The performance of the Cuban biotechnology from 2008 to 2021 has shown a
growing pipeline of valuable biomedical solutions. As transformation of
this sector into an industrial group has changed its R&D productivity
and biomanufacturing capacity, we summarize here results of R&D
projects with impact on public health, constraints found in Cuba,
lessons, and opportunities to develop this science-based industry in
developing countries.